The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication
Open Access
- 10 March 2015
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 112 (7), 1175-1182
- https://doi.org/10.1038/bjc.2015.62
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trialBritish Journal of Cancer, 2015
- Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South WalesBritish Journal of Cancer, 2014
- Comparison of fibulin-3 and mesothelin as markers in malignant mesotheliomaThorax, 2014
- Fibulin-3 as a Blood and Effusion Biomarker for Pleural MesotheliomaNew England Journal of Medicine, 2012
- A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusionsEuropean Respiratory Journal, 2012
- Inflammation-Based Prognostic Indices in Malignant Pleural MesotheliomaJournal of Thoracic Oncology, 2012
- Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor BurdenClinical Cancer Research, 2011
- High Blood Neutrophil-to-Lymphocyte Ratio Is an Indicator of Poor Prognosis in Malignant Mesothelioma Patients Undergoing Systemic TherapyClinical Cancer Research, 2010
- Modified RECIST criteria for assessment of response in malignant pleural mesotheliomaAnnals of Oncology, 2004
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2003